For further verification of whether Ltf attenuated adverse cardiac remodeling post-MI via mTORC1/S6K/eIF-4B axis, MHY1485 was administered intraperitoneally with a dosage of 10 mg/kg daily in mice (Figure 7A). Here, LTF is linked to myocardial infarction.